Restoring apoptosis as a strategy for cancer gene therapy: Focus on p53 and mda-7

Seminars in Cancer Biology

Volumn 13, Issue 2, 2003, Pages 169-178

  Lebedeva, Irina V ^a   Su, Zhao Zhong ^a   Sarkar, Devanand ^a   Fisher, Paul B ^a  

^a Columbia University ^*  (United States)

Author keywords

Adenovirus; Clinical trials; Gene therapy; mda 7 (IL 24); ONYX 015; p53; Programmed cell death

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL DESTRUCTION; CLINICAL MEDICINE; CYTOLYSIS; GENE EXPRESSION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; MELANOMA; MOLECULAR BIOLOGY; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; INTERLEUKINS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037375977     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00134-7     Document Type: Review

References (125)

1. Anderson W.F. Human gene therapy. Nature. 392:1998;25-30.
2. Galanis E., Vile R., Russell S.J. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. 38:2001;177-192.
3. Schatzlein A.G. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs. 12:2001;275-304.
4. Bergelson J.M., Cunningham J.A., Droguett G.et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1997;1320-1323.
5. Yang Y., Li Q., Ertl H.C.et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:1995;2004-2015.
6. Russell W.C. Update on adenovirus and its vectors. J. Gen. Virol. 81:2000;2573-2604.
7. Douglas J.T., Miller C.R., Kim M.et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat. Biotechnol. 17:1999;470-475.
8. Barnett B.G., Crews C.J., Douglas J.T. Targeted adenoviral vectors. Biochim. Biophys. Acta. 1575:2002;1-14.
9. Haviv Y.S., Curiel D.T. Conditional gene targeting for cancer gene therapy. Adv. Drug Deliv. Rev. 53:2001;135-154.
10. Springer C.J., Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 105:2000;1161-1167.
11. Buchsbaum D.J., Curiel D.T. Gene therapy for the treatment of cancer. Cancer Biother. Radiopharm. 16:2001;275-288.
12. Melief C.J., Toes R.E., Medema J.P.et al. Strategies for immunotherapy of cancer. Adv. Immunol. 75:2000;235-282.
13. Meyn R.E., Milas L., Stephens L.C. Apoptosis in tumor biology and therapy. Adv. Exp. Med. Biol. 400B:1997;657-667.
14. McGill G. Apoptosis in tumorigenesis and cancer therapy. Front. Biosci. 2:1997;d353-d379.
15. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
16. Momand J., Zambetti G.P., Olson D.C.et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
17. Caspari T. How to activate p53. Curr. Biol. 10:2000;R315-R317.
18. Harper J.W., Adami G.R., Wei N.et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
19. Tokino T., Nakamura Y. The role of p53-target genes in human cancer. Crit. Rev. Oncol. Hematol. 33:2000;1-6.
20. Murphy M., Ahn J., Walker K.K.et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13:1999;2490-2501.
21. Chen X., Ko L.J., Jayaraman L.et al. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:1996;2438-2451.
22. Marchenko N.D., Zaika A., Moll U.M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275:2000;16202-16212.
23. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
24. Lowe S.W., Ruley H.E., Jacks T.et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
25. Liu M.C., Gelmann E.P. P53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 29:2002;246-257.
26. Favrot M., Coll J.L., Louis N.et al. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther. 5:1998;728-739.
27. Chen P.L., Chen Y.M., Bookstein R.et al. Genetic mechanisms of tumor suppression by the human p53 gene. Science. 250:1990;1576-1580.
28. Yonish-Rouach E., Resnitzky D., Lotem J.et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
29. Fujiwara T., Cai D.W., Georges R.N.et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86:1994;1458-1462.
30. Nielsen L.L., Dell J., Maxwell E.et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4:1997;129-138.
31. Fujiwara T., Grimm E.A., Mukhopadhyay T.et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53:1993;4129-4133.
32. Fujiwara T., Grimm E.A., Mukhopadhyay T.et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
33. Gallardo D., Drazan K.E., McBride W.H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56:1996;4891-4893.
34. Nguyen D.M., Spitz F.R., Yen N.et al. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg. 112:1996;1372-1376. discussion 1376-7.
35. Nielsen L.L., Lipari P., Dell J.et al. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4:1998;835-846.
36. Gurnani M., Lipari P., Dell J.et al. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 44:1999;143-151.
37. Wen S.F., Xie L., McDonald M.et al. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Cancer Gene Ther. 7:2000;1469-1480.
38. Frank D.K., Frederick M.J., Liu T.J.et al. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin. Cancer Res. 4:1998;2521-2528.
39. Nishizaki M., Fujiwara T., Tanida T.et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin. Cancer Res. 5:1999;1015-1023.
40. Dameron K.M., Volpert O.V., Tainsky M.A.et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
41. Gautam A., Densmore C.L., Melton S.et al. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 9:2002;28-36.
42. Waku T., Fujiwara T., Shao J.et al. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer. J. Immunol. 165:2000;5884-5890.
43. NIH OBA Human Gene Transfer Clinical Trials Database. 2002.
44. Roth J.A., Nguyen D., Lawrence D.D.et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:1996;985-991.
45. Schuler M., Rochlitz C., Horowitz J.A.et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. 9:1998;2075-2082.
46. Swisher S.G., Roth J.A., Nemunaitis J.et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91:1999;763-771.
47. Kauczor H.U., Schuler M., Heussel C.P.et al. CT-guided intratumoral gene therapy in non-small-cell lung cancer. Eur. Radiol. 9:1999;292-296.
48. Yen N., Ioannides C.G., Xu K.et al. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther. 7:2000;530-536.
49. Weill D., Mack M., Roth J.et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest. 118:2000;966-970.
50. Nemunaitis J., Swisher S.G., Timmons T.et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18:2000;609-622.
51. Roth J.A., Swisher S.G., Merritt J.A.et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol. 25:1998;33-37.
52. Boulay J.L., Perruchoud A.P., Reuter J.et al. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients. Cancer Gene Ther. 7:2000;1215-1219.
53. Schuler M., Herrmann R., De Greve J.L.et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J. Clin. Oncol. 19:2001;1750-1758.
54. Clayman G.L., el-Naggar A.K., Lippman S.M.et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16:1998;2221-2232.
55. Clayman G.L., Frank D.K., Bruso P.A.et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5:1999;1715-1722.
56. Buller R.E., Runnebaum I.B., Karlan B.Y.et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9:2002;553-566.
57. Buller R.E., Shahin M.S., Horowitz J.A.et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 9:2002;567-572.
58. Dummer R., Bergh J., Karlsson Y.et al. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther. 7:2000;1069-1076.
59. Kuball J., Wen S.F., Leissner J.et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol. 20:2002;957-965.
60. Van Der Burg S.H., Menon A.G., Redeker A.et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. 8:2002;1019-1027.
61. Sweeney P., Pisters L.L. Ad5CMVp53 gene therapy for locally advanced prostate cancer - where do we stand? World J. Urol. 18:2000;121-124.
62. Kock H., Harris M.P., Anderson S.C.et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int. J. Cancer. 67:1996;808-815.
63. Gomez-Manzano C., Fueyo J., Kyritsis A.P.et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56:1996;694-699.
64. Badie B., Drazan K.E., Kramar M.H.et al. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol. Res. 17:1995;209-216.
65. Bampoe J., Glen J., Hubbard S.L.et al. Adenoviral vector-mediated gene transfer: timing of wild-type p53 gene expression in vivo and effect of tumor transduction on survival in a rat glioma brachytherapy model. J. Neurooncol. 49:2000;27-39.
66. Aka K., Bruner J.M., Bondy M.L.et al. Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. J. Neurooncol. 16:1993;125-133.
67. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292:1998;435-445.
68. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
69. Kemp C.J., Sun S., Gurley K.E. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 61:2001;327-332.
70. Zeimet A.G., Riha K., Berger J.et al. New insights into p53 regulation and gene therapy for cancer. Biochem. Pharmacol. 60:2000;1153-1163.
71. Donato N.J., Perez M., Kang H.et al. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin. Cancer Res. 6:2000;193-202.
72. Cordon-Cardo C., Latres E., Drobnjak M.et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:1994;794-799.
73. Eastham J.A., Hall S.J., Sehgal I.et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 55:1995;5151-5155.
74. Kagawa S., Pearson S.A., Ji L.et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther. 7:2000;75-79.
75. Bougeret C., Virone-Oddos A., Adeline E.et al. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2. Cancer Gene Ther. 7:2000;789-798.
76. Hemmati P.G., Gillissen B., von Haefen C.et al. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene. 21:2002;3149-3161.
77. Fueyo J., Gomez-Manzano C., Yung W.K.et al. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene. 12:1996;103-110.
78. Modesitt S.C., Ramirez P., Zu Z.et al. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin. Cancer Res. 7:2001;1765-1772.
79. Hunt K.K., Deng J., Liu T.J.et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 57:1997;4722-4726.
80. Bischoff J.R., Kirn D.H., Williams A.et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
81. Kao C.C., Yew P.R., Berk A.J. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology. 179:1990;806-814.
82. Rao L., Debbas M., Sabbatini P.et al. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7742-7746.
83. Barker D.D., Berk A.J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 156:1987;107-121.
84. Rogulski K.R., Freytag S.O., Zhang K.et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60:2000;1193-1196.
85. Ganly I., Kim Y.T., Hann B.et al. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene Ther. 8:2001;369-375.
86. Heise C., Sampson-Johannes A., Williams A.et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:1997;639-645.
87. Goodrum F.D., Ornelles D.A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:1998;9479-9490.
88. Rothmann T., Hengstermann A., Whitaker N.J.et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:1998;9470-9478.
89. Turnell A.S., Grand R.J., Gallimore P.H. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73:1999;2074-2083.
90. Ries S.J., Brandts C.H., Chung A.S.et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6:2000;1128-1133.
91. Heise C.C., Williams A.M., Xue S.et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59:1999;2623-2628.
92. Ganly I., Kirn D., Eckhardt G.et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6:2000;798-806.
93. Nemunaitis J., Ganly I., Khuri F.et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kDa gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60:2000;6359-6366.
94. Nemunaitis J., Khuri F., Ganly I.et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19:2001;289-298.
95. Khuri F.R., Nemunaitis J., Ganly I.et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6:2000;879-885.
96. Nemunaitis J., Cunningham C., Buchanan A.et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8:2001;746-759.
97. Habib N., Salama H., Abd El Latif Abu Median A.et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 9:2002;254-259.
98. Habib N.A., Sarraf C.E., Mitry R.R.et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. 12:2001;219-226.
99. Reid T., Galanis E., Abbruzzese J.et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8:2001;1618-1626.
100. Vasey P.A., Shulman L.N., Campos S.et al. Phase I trial of intraperitoneal injection of the E1B-55-kDa-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20:2002;1562-1569.
101. Mulvihill S., Warren R., Venook A.et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 8:2001;308-315.
102. Hecht J.R., Abbruzzese J., Bedford R.et al. A phase I/II trial of intratumoral endoscopic injection of Onyx-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. 19:2000;1039. [abstract].
103. Babiss L.E., Ginsberg H.S., Darnell J.E. Jr. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell. Biol. 5:1985;2552-2558.
104. Yang C.T., You L., Uematsu K.et al. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 61:2001;5959-5963.
105. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
106. Heise C., Hermiston T., Johnson L.et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6:2000;1134-1139.
107. Johnson L., Shen A., Boyle L.et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell. 1:2002;325-337.
108. Jiang H., Lin J.J., Su Z.Z.et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 11:1995;2477-2486.
109. Zhang R., Tan Z., Liang P. Identification of a novel ligand-receptor pair constitutively activated by ras oncogenes. J. Biol. Chem. 275:2000;24436-24443.
110. Huang E.Y., Madireddi M.T., Gopalkrishnan R.V.et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene. 20:2001;7051-7063.
111. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V.et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J. Biol. Chem. 276:2001;2725-2732.
112. Madireddi M.T., Su Z.Z., Young C.S.H.et al. Mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy. Adv. Exp. Med. Biol. 465:2000;239-261.
113. Sarkar D, Su Z-Z, Lebedeva IV, et al. mda-7/IL-24: signaling and functional role. BioTechniques 2002;Suppl:30-9.
114. Caudell E.G., Mumm J.B., Poindexter N.et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J. Immunol. 168:2002;6041-6046.
115. Jiang H., Su Z.Z., Lin J.J.et al. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc. Natl. Acad. Sci. U.S.A. 93:1996;9160-9165.
116. Mhashilkar A.M., Schrock R.D., Hindi M.et al. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol. Med. 7:2001;271-282.
117. Su Z.Z., Madireddi M.T., Lin J.J.et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl. Acad. Sci. U.S.A. 95:1998;14400-14405.
118. Ekmekcioglu S., Ellerhorst J., Mhashilkar A.M.et al. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int. J. Cancer. 94:2001;54-59.
119. Ellerhorst J.A., Prieto V.G., Ekmekcioglu S.et al. Loss of MDA-7 expression with progression of melanoma. J. Clin. Oncol. 20:2002;1069-1074.
120. Lebedeva I.V., Su Z.Z., Chang Y.et al. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene. 21:2002;708-718.
121. Saeki T., Mhashilkar A., Chada S.et al. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther. 7:2000;2051-2057.
122. Lebedeva IV, Fisher PB. 2002; unpublished data.
123. Pataer A., Vorburger S.A., Barber G.N.et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda-7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res. 62:2002;2239-2243.
124. Su Z., Lebedeva I.V., Gopalkrishnan R.V.et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10332-10337.
125. Saeki T., Mhashilkar A., Swanson X.et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene. 21:2002;4558-4566.